NCT03855982

Brief Summary

Several drugs and chemotherapies seem to induce myocarditis. This study investigates reports of myocarditis, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 25, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 27, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

April 9, 2019

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 25, 2020

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 4, 2023

Completed
Last Updated

April 5, 2023

Status Verified

April 1, 2023

Enrollment Period

11 months

First QC Date

February 25, 2019

Last Update Submit

April 4, 2023

Conditions

Keywords

myocardial toxicitychemotherapiesdrugs

Outcome Measures

Primary Outcomes (1)

  • Number of myocarditis induced by drugs and report of cases of myocarditis associated with drugs.

    Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

Secondary Outcomes (7)

  • Causality assessment of reported myocarditis events according to the WHO system

    Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

  • Description of the myocarditis depending on the category of drug

    Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

  • Description of the other related adverse events concomitant to the myocarditis induced by drugs

    Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

  • Description of the duration of treatment when the toxicity happens (role of cumulative dose)

    Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

  • Description of the drug-drug interactions associated with adverse events

    Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

  • +2 more secondary outcomes

Study Arms (1)

myocarditis induced by drugs and chemotherapies

Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity

Drug: Drug inducing myocarditis

Interventions

Drugs susceptible to induce myocarditis

myocarditis induced by drugs and chemotherapies

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients treated with a drug that could be reported in the WHO's pharmacovigilance database

You may qualify if:

  • Case reported in the WHO's pharmacovigilance database till 25/02/2019

You may not qualify if:

  • Chronology not compatible between the drug and the toxicity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM

Paris, 75013, France

Location

MeSH Terms

Conditions

MyocarditisHeart Failure

Condition Hierarchy (Ancestors)

CardiomyopathiesHeart DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant director, clinical investigation center Paris Est

Study Record Dates

First Submitted

February 25, 2019

First Posted

February 27, 2019

Study Start

April 9, 2019

Primary Completion

February 25, 2020

Study Completion

April 4, 2023

Last Updated

April 5, 2023

Record last verified: 2023-04

Locations